Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462576 · ClinicalTrials.gov registry record
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
A clinical trial, sponsored by Meridian Bioscience.
- Terminated
- Registry status
- 199
- Enrollment target
NCT03462576: Clinical Trial study, sponsored by Meridian Bioscience.
NCT03462576 is a clinical trial that was terminated before completion, run by Meridian Bioscience. The registered enrollment target is 199 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03462576 was terminated before completion, sponsored by Meridian Bioscience.
- TERMINATED
- Registry status
- 199 participants
- Enrollment target
Study Summary
This study is a companion protocol that will use the data generated by Conatus' study of emricasan under protocol IDN-6556-17.The IDN-6556-17 study is a Phase 2, multicenter, double-blind, placebo-controlled trial of Emricasan in subjects with decompensated non-alcoholic steatohepatitis (NASH) cirrhosis.
Primary Outcome
Binary diagnosis of subjects that are at high risk to develop a deterioration event as determined by the Methacetin Breath Test (MBT) derived from an algorithm developed under other Exalenz clinical studies using a pre-designed cutoff of Percentage Dose Recovery (PDR) peak of \< 5.5%/hour. The data was collected and analyzed agnostic to the intervention.
Interventions
- DRUG Placebo oral capsule
- DRUG Emricasan
- COMBINATION_PRODUCT Methacetin Breath Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2019-07-15 |
Why NCT03462576 stopped before completion
NCT03462576 is an interventional study that assigns participants to a tested intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03462576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03462576 about?
NCT03462576 is a clinical study titled "Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17". This study is a companion protocol that will use the data generated by Conatus' study of emricasan under protocol IDN-6556-17.The IDN-6556-17 study is a Phase 2, multicenter, double-blind, placebo-controlled trial of Emricasan in subjects with decompensated non-alcoholic steatohepatitis (NASH) cirrh...
What is the current status of trial NCT03462576?
This trial is currently terminated. The enrollment target is 199 participants. The study started on 2017-06-28. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03462576?
The interventions under investigation include: Placebo oral capsule (DRUG), Emricasan (DRUG), Methacetin Breath Test (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03462576?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI